Published in Melanoma Res on August 01, 1997
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One (2007) 2.77
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature (2010) 2.49
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62
RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell (2005) 1.59
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res (2008) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta (2011) 1.36
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer (2010) 1.27
β-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS One (2011) 1.25
Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol (2005) 1.19
Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol (2004) 1.18
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res (2007) 1.14
Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene (2005) 1.13
Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem (2004) 1.06
Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther (2009) 1.04
Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem (2005) 1.02
Transcriptional profiling of human endogenous retrovirus group HERV-K(HML-2) loci in melanoma. Genome Biol Evol (2013) 1.01
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis (2008) 0.99
BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res (2014) 0.99
ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep (2015) 0.98
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression. J Biol Chem (2006) 0.98
Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol (2001) 0.97
Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma. Exp Cell Res (2010) 0.95
Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression. Exp Cell Res (2006) 0.94
Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Cancer Res (2009) 0.94
Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res (2007) 0.91
Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem (2009) 0.90
Merlin is a negative regulator of human melanoma growth. PLoS One (2012) 0.89
The chick embryo as an experimental system for melanoma cell invasion. PLoS One (2013) 0.89
Modulation of SOCS protein expression influences the interferon responsiveness of human melanoma cells. BMC Cancer (2010) 0.88
MiR-21 enhances melanoma invasiveness via inhibition of tissue inhibitor of metalloproteinases 3 expression: in vivo effects of MiR-21 inhibitor. PLoS One (2015) 0.88
alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell Melanoma Res (2010) 0.88
Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells. Exp Cell Res (2006) 0.87
K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. J Leukoc Biol (2011) 0.87
Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther (2012) 0.86
A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme. Mol Cell Proteomics (2009) 0.86
From melanocytes to melanomas. Nat Rev Cancer (2016) 0.85
UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. J Invest Dermatol (2015) 0.85
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One (2015) 0.84
Melanoma prevention using topical PBISe. Cancer Prev Res (Phila) (2011) 0.84
Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis (2011) 0.84
Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res (2011) 0.84
Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J Cell Biochem (2011) 0.83
Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma. Mol Cancer Ther (2012) 0.82
Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther (2014) 0.81
Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS One (2015) 0.77
Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res (2014) 0.77
Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. Apoptosis (2015) 0.76
Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma. Mol Cancer Res (2016) 0.75
A simple engineered platform reveals different modes of tumor-microenvironmental cell interaction. Biofabrication (2015) 0.75
Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway. Mol Cancer Res (2015) 0.75
Generation of metastatic melanoma specific antibodies by affinity purification. Sci Rep (2016) 0.75
Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Proc Natl Acad Sci U S A (2017) 0.75
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat Commun (2017) 0.75
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res (1990) 4.22
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci (1998) 2.58
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res (2001) 2.47
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med (1993) 2.24
Human melanoma progression in skin reconstructs : biological significance of bFGF. Am J Pathol (2000) 2.23
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
Human hair follicle bulge cells are biochemically distinct and possess an epithelial stem cell phenotype. J Investig Dermatol Symp Proc (1999) 1.96
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res (1994) 1.86
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J (1989) 1.84
Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol (1982) 1.76
Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res (2001) 1.75
Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 1.74
Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol (2000) 1.74
Extraadrenal myelolipoma: MR imaging findings. AJR Am J Roentgenol (1998) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
The complete cDNA and polypeptide sequences of human erythroid alpha-spectrin. J Biol Chem (1990) 1.71
Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A (1999) 1.68
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A (1993) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene (2001) 1.59
Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol (1979) 1.59
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A (1990) 1.57
Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer (2007) 1.57
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A (1986) 1.54
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol (1998) 1.50
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J Nucl Med (1999) 1.46
Repression of rearranged mu gene and translocated c-myc in mouse 3T3 cells X Burkitt lymphoma cell hybrids. Science (1984) 1.46
Cloning of a portion of the chromosomal gene for human erythrocyte alpha-spectrin by using a synthetic gene fragment. Proc Natl Acad Sci U S A (1986) 1.45
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44
Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci U S A (1986) 1.44
Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci (2000) 1.44
Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest (2000) 1.42
Human/severe combined immunodeficient mouse chimeras. An experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin Invest (1993) 1.42
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res (2001) 1.40
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol (1993) 1.39
Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res (1994) 1.38
Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods (1984) 1.37
Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest (1993) 1.36
Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors. Hum Gene Ther (2001) 1.36
Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol (1991) 1.35
Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. Proc Natl Acad Sci U S A (1990) 1.35
Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet (1986) 1.34
Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc (1996) 1.33
Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet (2004) 1.32
Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol (2001) 1.31
Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol (1982) 1.31
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med (2012) 1.30
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res (1999) 1.28
Regulation of extracellular matrix proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound healing in vivo. Am J Pathol (1993) 1.28
Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer (1999) 1.28
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene (2010) 1.26
Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ (2000) 1.25
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res (1995) 1.25
Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res (2000) 1.25
Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol (1997) 1.23
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol (1993) 1.23
Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res (1997) 1.20
Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene (2007) 1.19
Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest (1984) 1.18
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol (1999) 1.17
Biochemical and functional characterization of aminopeptidase N expressed by human melanoma cells. Cancer Res (1993) 1.17